These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

262 related items for PubMed ID: 35092343

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Laboratory diagnosis and molecular classification of von Willebrand disease.
    Gadisseur A, Hermans C, Berneman Z, Schroyens W, Deckmyn H, Michiels JJ.
    Acta Haematol; 2009; 121(2-3):71-84. PubMed ID: 19506352
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. von Willebrand factor propeptide and the phenotypic classification of von Willebrand disease.
    Sanders YV, Groeneveld D, Meijer K, Fijnvandraat K, Cnossen MH, van der Bom JG, Coppens M, de Meris J, Laros-van Gorkom BA, Mauser-Bunschoten EP, Leebeek FW, Eikenboom J, WiN study group.
    Blood; 2015 May 07; 125(19):3006-13. PubMed ID: 25673639
    [Abstract] [Full Text] [Related]

  • 6. Evaluation of the Utility of von Willebrand Factor Propeptide in the Differential Diagnosis of von Willebrand Disease and Acquired von Willebrand Syndrome.
    Stufano F, Boscarino M, Bucciarelli P, Baronciani L, Maino A, Cozzi G, Peyvandi F.
    Semin Thromb Hemost; 2019 Feb 07; 45(1):36-42. PubMed ID: 29913537
    [Abstract] [Full Text] [Related]

  • 7. Characterization of recessive severe type 1 and 3 von Willebrand Disease (VWD), asymptomatic heterozygous carriers versus bloodgroup O-related von Willebrand factor deficiency, and dominant type 1 VWD.
    Michiels JJ, Berneman Z, Gadisseur A, van der Planken M, Schroyens W, van de Velde A, van Vliet H.
    Clin Appl Thromb Hemost; 2006 Jul 07; 12(3):277-95. PubMed ID: 16959681
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Assay of the von Willebrand factor (VWF) propeptide to identify patients with type 1 von Willebrand disease with decreased VWF survival.
    Haberichter SL, Balistreri M, Christopherson P, Morateck P, Gavazova S, Bellissimo DB, Manco-Johnson MJ, Gill JC, Montgomery RR.
    Blood; 2006 Nov 15; 108(10):3344-51. PubMed ID: 16835381
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Molecular pathogenesis and heterogeneity in type 3 VWD families in U.S. Zimmerman program.
    Christopherson PA, Haberichter SL, Flood VH, Perry CL, Sadler BE, Bellissimo DB, Di Paola J, Montgomery RR, Zimmerman Program Investigators.
    J Thromb Haemost; 2022 Jul 15; 20(7):1576-1588. PubMed ID: 35343054
    [Abstract] [Full Text] [Related]

  • 14. Identification of type 1 von Willebrand disease patients with reduced von Willebrand factor survival by assay of the VWF propeptide in the European study: molecular and clinical markers for the diagnosis and management of type 1 VWD (MCMDM-1VWD).
    Haberichter SL, Castaman G, Budde U, Peake I, Goodeve A, Rodeghiero F, Federici AB, Batlle J, Meyer D, Mazurier C, Goudemand J, Eikenboom J, Schneppenheim R, Ingerslev J, Vorlova Z, Habart D, Holmberg L, Lethagen S, Pasi J, Hill FG, Montgomery RR.
    Blood; 2008 May 15; 111(10):4979-85. PubMed ID: 18344424
    [Abstract] [Full Text] [Related]

  • 15. Bleeding prophylaxis for major surgery in patients with type 2 von Willebrand disease with an intermediate purity factor VIII-von Willebrand factor concentrate (Haemate-P).
    Michiels JJ, Berneman ZN, van der Planken M, Schroyens W, Budde U, van Vliet HH.
    Blood Coagul Fibrinolysis; 2004 Jun 15; 15(4):323-30. PubMed ID: 15166918
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Correlation between von Willebrand factor antigen, von Willebrand factor ristocetin cofactor activity and factor VIII activity in plasma.
    Lippi G, Franchini M, Salvagno GL, Montagnana M, Poli G, Guidi GC.
    J Thromb Thrombolysis; 2008 Oct 15; 26(2):150-3. PubMed ID: 17786534
    [Abstract] [Full Text] [Related]

  • 18. Genome-wide studies of von Willebrand factor propeptide identify loci contributing to variation in propeptide levels and von Willebrand factor clearance.
    Ozel AB, McGee B, Siemieniak D, Jacobi PM, Haberichter SL, Brody LC, Mills JL, Molloy AM, Ginsburg D, Li JZ, Desch KC.
    J Thromb Haemost; 2016 Sep 15; 14(9):1888-98. PubMed ID: 27359253
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.